Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Abstract

a Background and Aims. Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. Methods. A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. Results. The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. Conclusion. Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.

The lipoxygenase‐hepoxilin pathway is activated in cutaneous plaque lesions of psoriasis

“…14 The relationship between skin and joint manifestations is not clear. 15,17 In the present study, interestingly, PGE 1 and PGE 3 were more highly expressed in the skin samples from PsA than in those from PV. 16 Recently, a group for the research and assessment of psoriasis and psoriatic arthritis proposed serum biomarkers including interleukin-6, matrix metalloproteinase-3, and others as markers to distinguish PsA from PV.…”

“…16 Recently, a group for the research and assessment of psoriasis and psoriatic arthritis proposed serum biomarkers including interleukin-6, matrix metalloproteinase-3, and others as markers to distinguish PsA from PV. 15,17 In the present study, interestingly, PGE 1 and PGE 3 were more highly expressed in the skin samples from PsA than in those from PV. Different from PGE 2 , PGE 1 has anti-inflammatory effects on endothelial cells and certain subsets of leukocytes.…”

“…15 Although early diagnosis may lead to early treatment and benefits for PsA patients, the reliable prediction of PsA development in PV patients has not been established. 14 The relationship between skin and joint manifestations is not clear.…”

“…14 The relationship between skin and joint manifestations is not clear. 15 Although early diagnosis may lead to early treatment and benefits for PsA patients, the reliable prediction of PsA development in PV patients has not been established. 16 Recently, a group for the research and assessment of psoriasis and psoriatic arthritis proposed serum biomarkers including interleukin-6, matrix metalloproteinase-3, and others as markers to distinguish PsA from PV.…”

Treatment Effects upon Prolactin and Soluble Receptor of Interleukin-2 in Psoriatic Patients

“…Then, they discontinued bromocriptin and all cases had relapsed in psoriasis. In 2015, Husakova et al demonstrated a correlation between increased PRL serum levels and psoriatic arthritis; therefore, elevated PRL serum levels might represent a marker of inflammatory joint disease in patients suffering from psoriasis vulgaris (26).…”